Lung Cancer Research

2010

• 

  Trever Bivona, MD, PhD

  EGFR-targeted therapies are initially very successful in patients with EGFR-activating mutations, but those patients eventually become resistant. In some cases, patients develop an additional...

  | More…
• 

  Lauren Averett Byers, MD, MS and John Heymach, MD

  Small cell lung cancer is highly aggressive, with most patients quickly becoming resistant to standard chemotherapy. New molecularly targeted therapies are needed. Drs. Byers and Heymach are...

  | More…
• 

  James DeGregori, PhD

  Dr. DeGregori is seeking ways to overcome resistance to EGFR-targeted therapies. Dr. DeGregori and his team identified a number of other targets that could be inhibited to increase...

  | More…
• 

  Sarah Freemantle, PhD

  MicroRNAs are small RNA molecules that can control expression of almost one-third of all known genes. Dr. Freemantle and colleagues have shown increased expression of one of these microRNAs, miRNA...

  | More…
• 

  Heidi Greulich, PhD

  Molecularly-targeted therapies have proven more effective than standard chemotherapy in the treatment of lung cancer. In many cases, genes activated by a specific mutation have shown to be...

  | More…
• 

  Christine Lovly, MD, PhD

  Molecularly-targeted therapies have proven more effective than standard chemotherapy in the treatment of lung cancer. For example, patients harboring EGFR mutations initially respond very well to...

  | More…
• 

  Don Nguyen, PhD

  A long-standing clinical observation is that by the time cancers have spread to other organs, they are generally untreatable. In the case of lung cancer, tumors acquire resistance to different...

  | More…
• 

  Paul Paik, MD

  Many lung cancer patients who have mutations to the EGFR gene initially respond well to EGFR-targeted therapies; unfortunately, patients can quickly develop resistance to this therapy. However, it...

  | More…
• 

  Katerina Politi, PhD

  Many lung cancer patients who have mutations to the EGFR gene initially respond well to EGFR-targeted therapies; unfortunately, patients can quickly develop resistance to this therapy. In 50% of...

  | More…
• 

  Julien Sage, PhD

  Early detection of cancer remains one of the most important factors in successful treatment. Using a preclinicalmodel of small cell lung cancer, Dr. Sage will be investigating novel blood...

  | More…